MK-677
Also known as: Ibutamoren, MK-0677, L-163,191
Molecular Identifiers
Overview
Oral non-peptidic ghrelin receptor (GHS-R1a) agonist that promotes sustained GH and IGF-1 secretion. Unlike GHRP peptides, it is orally bioavailable with a long half-life, maintaining elevated GH levels for up to 24 hours.
Small non-peptidic molecule. Oral ghrelin receptor agonist.
Half-life
~24 hours
Administration Route
Oral
Category
GH Secretagogues
Mechanism of Action
- Oral ghrelin receptor (GHS-R1a) agonism
- Sustained GH secretion for 24 hours
- Elevation of serum IGF-1
- Mimicry of physiological GH pattern (amplified pulses)
- Appetite increase via ghrelin signaling
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 10-25 mg per dose |
| Frequency | Once daily |
| Timing | Before bedtime (to minimize GH effects on sleep) |
| Duration | 8-12 weeks |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Increased appetite (very common)
- Water retention
- Numbness/tingling
- Elevated blood glucose
- Lethargy
- Joint pain
Product Properties
| Purity | >99% |
| Appearance | White capsules or tablets |
| Source | Chemical synthesis |
Presentations & Preparation
Vials of MK-677 found in the research market:
Reconstitution
- Diluent: N/A (capsules or tablets)
- Volume: N/A
- Supplied as capsules or tablets
- Administer with or without food
Storage
- Lyophilized: Room temperature
- Reconstituted: N/A
- Keep in a dry place
- Protect from light and moisture
Related Peptides
CJC-1295 with DAC
1-2 mg per week · Once per week
CJC-1295 sem DAC
100-200 mcg per injection · 2-3 times daily
GHRP-2
100-300 mcg per injection · 2-3 times per day
GHRP-6
100-300 mcg per injection · 2-3 times per day
Hexarelin
200-300 mcg per injection · 2-3 times per day
Ipamorelin
200-300 mcg per injection · 2-3 times daily